Stepan (NYSE:SCL – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Sunday.
Stepan Price Performance
Shares of NYSE:SCL opened at $74.74 on Friday. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 37.18 and a beta of 0.81. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.27 and a quick ratio of 0.86. Stepan has a 12 month low of $69.78 and a 12 month high of $96.68. The stock’s 50 day moving average price is $75.26 and its 200 day moving average price is $80.24.
Stepan (NYSE:SCL – Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The basic materials company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.38. The company had revenue of $546.84 million for the quarter, compared to analysts’ expectations of $577.23 million. Stepan had a return on equity of 4.56% and a net margin of 2.10%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the firm earned $0.64 EPS. Equities research analysts anticipate that Stepan will post 2.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Stepan Company Profile
Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products worldwide. It operates through three segments: Surfactants, Polymers, and Specialty Products. The Surfactants segment offers surfactants that are used in consumer and industrial cleaning and disinfection products, including detergents for washing clothes, dishes, carpets, and floors and walls, as well as shampoos and body washes; and other applications, such as fabric softeners, germicidal quaternary compounds, disinfectants, and lubricating ingredients.
Read More
- Five stocks we like better than Stepan
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- The Significance of Brokerage Rankings in Stock Selection
- Time to Load Up on Home Builders?
Receive News & Ratings for Stepan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stepan and related companies with MarketBeat.com's FREE daily email newsletter.